For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Zoetis Inc. (ZTS) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-07): Designation Watch · Gem Score +29 (−100…+100 Quality+Value blend) · Quality 69 · Value 3 · Sentiment 6 (timing only, not weighted) · Composite fair value $94.93 vs $77.30 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Zoetis Inc.
ZTS NYSEZoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock. Zoetis develops and markets products used by veterinarians, livestock producers, and pet owners across companion animals such as dogs, cats, and horses, as well as livestock including cattle, swine, poultry, fish, and sheep. Its portfolio includes parasiticides, dermatology treatments, pain and sedation products, anti-infectives, diagnostic tools, genetic tests, and precision animal health solutions. The company also provides reference laboratory services, rapid tests, instruments, and other non-pharmaceutical offerings that support disease detection and animal care. Headquartered in Parsippany, New Jersey, Zoetis operates in the United States and international markets, serving a broad range of animal health needs across clinical, agricultural, and diagnostic settings.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 6.02
Total Equity: $3.33B
Shares: 443,835,000
Total Debt: $9.04B
Cash: $2.31B
EBITDA: $4.91B
Total Debt: $9.04B
Cash: $2.31B
Revenue: $9.47B
Revenue: $9.47B
Revenue: $9.47B
Total Equity: $3.33B
Tax Rate: 20.4%
Equity: $3.33B
Total Debt: $9.04B
Cash: $2.31B
Current Liabilities: $2.24B
Long-Term Debt: $9.04B
Total Debt: $9.04B
Total Equity: $3.33B
Shares: 443,835,000
Shares: 443,835,000
CapEx: -$621.00M
Shares: 443,835,000
Stock Price: $77.30
Net Income: $2.67B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 24, 2026 3:09pm (44d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $7.8B | $8.1B | $8.5B | $9.3B | $9.5B |
| Cost of Revenue | $2.3B | $2.5B | $2.6B | $2.7B | $2.7B |
| Gross Profit | $5.5B | $5.6B | $6.0B | $6.5B | $6.8B |
| Operating Expenses | $2.0B | $2.0B | $2.2B | $2.3B | $2.4B |
| Operating Income | $3.5B | $3.6B | $3.8B | $4.2B | $4.4B |
| Net Income | $2.0B | $2.1B | $2.3B | $2.5B | $2.7B |
| EBITDA | $3.9B | $4.1B | $4.3B | $4.7B | $4.9B |
| EPS | $4.29 | $4.51 | $5.08 | $5.47 | $6.03 |
| EPS (Diluted) | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 |
Balance Sheet (Annual)
Last updated: Aug 14, 2026 11:19am (54d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.5B | $3.6B | $2.0B | $2.0B | $2.3B |
| Total Current Assets | $6.9B | $7.5B | $6.3B | $6.0B | $6.8B |
| Total Assets | $13.9B | $14.9B | $14.3B | $14.2B | $15.5B |
| Current Liabilities | $1.8B | $3.2B | $1.9B | $3.4B | $2.2B |
| Long-Term Debt | $6.6B | $6.6B | $6.6B | $5.2B | $9.0B |
| Total Liabilities | $9.4B | $10.5B | $9.3B | $9.5B | $12.1B |
| Total Equity | $4.5B | $4.4B | $5.0B | $4.8B | $3.3B |
| Retained Earnings | $7.2B | $8.7B | $10.3B | $12.0B | $13.7B |
Cash Flow (Annual)
Last updated: Aug 24, 2026 3:09pm (44d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.2B | $1.9B | $2.4B | $3.0B | $2.9B |
| Capital Expenditure | -$477.0M | -$586.0M | -$732.0M | -$655.0M | -$621.0M |
| Free Cash Flow | $1.7B | $1.3B | $1.6B | $2.3B | $2.3B |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | -$600.0M | $1.3B | -$1.4B | $0 | $498.0M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$743.0M | -$1.6B | -$1.1B | -$1.9B | -$3.2B |
| Net Change in Cash | -$119.0M | $96.0M | -$1.5B | -$54.0M | $325.0M |
Growth Trends (YoY %)
Last updated: Aug 24, 2026 3:09pm (44d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +3.9% | +5.7% | +8.3% | +2.3% |
| Gross Profit Growth | +2.8% | +6.3% | +9.3% | +4.0% |
| Operating Income Growth | +4.2% | +5.9% | +10.1% | +4.8% |
| Net Income Growth | +3.8% | +10.9% | +6.1% | +7.5% |
| EBITDA Growth | +4.1% | +5.9% | +9.1% | +4.1% |
Dividend History (Last 20)
Last updated: Aug 24, 2026 2:38pm (44d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-20 | $0.53 | — | — | — |
| 2026-04-20 | $0.53 | — | — | — |
| 2026-01-20 | $0.53 | — | — | — |
| 2025-10-31 | $0.50 | — | — | — |
| 2025-07-18 | $0.50 | — | — | — |
| 2025-04-21 | $0.50 | — | — | — |
| 2025-01-21 | $0.50 | — | — | — |
| 2024-10-31 | $0.43 | — | — | — |
| 2024-07-18 | $0.43 | — | — | — |
| 2024-04-18 | $0.43 | — | — | — |
| 2024-01-18 | $0.43 | — | — | — |
| 2023-10-31 | $0.38 | — | — | — |
| 2023-07-20 | $0.38 | — | — | — |
| 2023-04-20 | $0.38 | — | — | — |
| 2023-01-19 | $0.38 | — | — | — |
| 2022-10-31 | $0.33 | — | — | — |
| 2022-07-20 | $0.33 | — | — | — |
| 2022-04-20 | $0.33 | — | — | — |
| 2022-01-19 | $0.33 | — | — | — |
| 2021-10-28 | $0.25 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-02 02:04A +1σ run of quarters pays +4%; a −1σ run costs 16%. Ratio 0.3:1 (μ 3.1%, σ 3.4% , 16 pairs).
Older method (repeat-worst-quarter): -0.1 : 1
| Case | Growth | Margin | Fair value | vs price ($77.30) |
|---|---|---|---|---|
| Bull — recovery | +1% | 31.8% | $76.02 | -2% |
| Base — stabilizes | +1% | 27.7% | $66.46 | -14% |
| Bear — keeps slipping | +0% | 23.5% | $57.07 | -26% |
| Stress — last quarter repeats | -0% | 27.7% | $64.77 | -16% |
| Upside — a +1σ run of quarters (v2) | +6% | 27.7% | $80.66 | +4% |
| Stress — a −1σ run of quarters (v2) | -0% | 27.7% | $64.71 | -16% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-25 18:10The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw numbers tell a cleaner story than the model chorus suggests. Zoetis is compounding revenue at ~5% (9.47B in 2025 vs 7.78B in 2021, ~5.0% CAGR), operating income at ~6.2%, and net income at ~6.9% — classic specialty pharma with modest operating leverage. The quarterly sequence is more revealing: Q2'26 rev of $2.47B matches Q2'25 exactly ($2.47B), and TTM revenue is running ~$9.53B vs 2025's $9.47B — decidedly low-single-digit, not the mid-single-digit growth the bull deck implies. Margins have held (Q2'26 NI margin 28% vs Q2'25 29.3%), so the fortress isn't cracking, but it isn't expanding either. At $77.30 with 12.8x earnings, 8x EV/EBITDA, and a 35% ROIC, this is being priced like a mature cash cow with growth risk — which is roughly what it is.
Where I part ways with the synthesis: the $94-98 fair value composite feels aggressive given decelerating YoY (recent 2.3%). A more defensible frame is EV/EBITDA at ~10-11x (a reasonable multiple for a 35% ROIC, low-growth specialty pharma leader) on roughly $4.6B EBITDA → EV ~$48B, less $6.7B net debt = ~$41B equity, or ~$100/share IF you believe 10-11x is warranted. But specialty pharma peers with 3-5% growth typically trade at 8-10x; at 9x EBITDA you get ~$85/share. So my fair value band is $80-95, not $94-98. The synthesis is probably right in direction but overstates the gap. The thesis-evaluation "score of 0" is closer to honest than the "undervalued +22%" verdict.
The contrarian argument has real teeth and the models undersell it. Debt-to-equity moved from 1.32 to 2.71 while equity shrunk to just $3.33B against $9.04B debt — this is aggressive buyback-funded financial engineering, not organic value creation, and it inflates ROE (80%) to a meaningless number. If growth stalls at 2-3% and rates stay elevated, the leverage becomes a drag rather than an accretion story. The "significant insider buying" tag is misleading — the transaction list shows gifts and awards (G, A codes), not open-market purchases (P). No insider is putting cash in. The narrative layer's claim of "meaningful insider buying" appears to be a factual error propagated through multiple downstream models. Also worth flagging: the data timestamps (2026-06-30, 2026-08-07) suggest we're mid-2026, so the "50% discount to 52-week high" framing needs verification — this could be a genuine broken-growth story the market is correctly pricing, not a mispricing.
Net view: I partially agree with the undervalued call but with lower conviction and a tighter fair-value band. At $77 you're paying 12.8x earnings and ~14x FCF for a business generating $2.28B FCF, 35% ROIC, and defensive end-market exposure — that's cheap on quality-adjusted metrics. But you're also buying decelerating top-line (2.3% recent YoY), a levered balance sheet where equity has been engineered down, and no visible catalyst. Fair value is $85-90, not $94-98. The 10-15% upside plus 2.7% dividend is a decent risk-adjusted return but not a table-pounder, and the models — particularly the narrative and thesis-evaluation layers — are more balanced than the "undervalued +22%" headline. I'd be a buyer under $72, a holder at $77, and would trim above $90 absent evidence of growth re-acceleration in the next two quarterly prints. The insider "buying" signal should be discarded; it's noise mislabeled as signal.
GPT Reading
At $77.30, Zoetis looks cheap on the supplied multiples, but the raw financials say this is not a broken franchise being gifted away. Revenue has risen from $7.78B in 2021 to $9.47B in 2025, a 5%+ annual clip on a large base, while net income climbed from $2.04B to $2.67B and operating income from $3.47B to $4.42B. What stands out most is not growth, which is respectable but not exciting, but consistency: gross margin is still 71.8%, operating margin 46.7%, and net margin 28.2%. Quarterly margins have stayed in a tight, elite band of 25%-30% even as quarterly revenue has moved only between roughly $2.2B and $2.47B. That is a very high-quality earnings stream for a so-called mature animal health company. On trailing annualized earnings power using the last four quarters, net income is about $2.64B; against a $31.94B market cap, that implies a P/E near 12x, which is unusually low for a business with 35% ROIC and this level of resilience.
The more important point is that the business is still growing enough to matter. The latest quarter, June 2026, showed revenue of $2.47B, exactly matching June 2025, so the headline on that quarter is flat sales. But that needs context. March 2026 revenue was $2.26B versus $2.20B a year earlier, up 2.7%, and net income was essentially flat to slightly down from $602M to $601M before rebounding to $691M in June from $726M the prior year. That pattern is not a collapse; it is a plateau after several years of expansion. Meanwhile, full-year 2025 revenue still grew to $9.47B from $9.26B, and net income to $2.67B from $2.49B. If this is what the market is treating as a de-rated defensive compounder, I think it has overreacted. Even on free cash flow, $2.28B in 2025 is a 7.1% FCF yield on the current market cap, and that is before giving any credit for continued mid-single-digit growth or operating leverage.
The contradiction I see is between the market apparently valuing Zoetis like a low-growth, potentially ex-growth pharma name and the actual economics of the business. A company earning nearly $2.7B annually, converting $2.9B of operating cash flow, and sustaining near-30% net margins should not normally trade at 3.6x sales and under 8x EV/EBITDA unless there is a real impairment coming. Nothing in the data provided shows that impairment yet. Debt is meaningful at $9.04B against $2.31B cash and only $3.33B equity, but the debt load is quite manageable against $4.42B of operating income and $2.28B of FCF. The high debt-to-equity and 80% ROE are more balance-sheet optics than business weakness; equity is simply small relative to the earnings base. For me, this screens as a high-quality defensive compounder whose multiple has compressed too far relative to its still-intact earnings power.
The best bear case is straightforward and stronger than bulls should admit. Growth has plainly slowed. Annual revenue growth fell to 2.3% in the most recent full year, and the latest June quarter was flat year over year. If that flat-to-low-single-digit cadence persists, then this deserves a lower multiple than the premium consumer-health or specialty-pharma analogs it used to resemble. The balance sheet also is not pristine: debt of $9.04B versus equity of $3.33B means leverage has done some of the work in juicing returns, and capex of $621M is not trivial. If this business has moved from a 5%-7% top-line grower to a 1%-3% grower, then a 12x earnings multiple may be less “cheap” than it first appears. I also discount the insider read entirely here: the transactions shown are gifts and awards, not open-market buying, so I do not see insider behavior in this dataset as bullish evidence at all.
What would change my mind is not a narrative shift but proof in the numbers that the slowdown is becoming structural. If the next two quarters show revenue stuck around $2.2B-$2.4B with no year-over-year growth and net margin slipping toward 24%-25%, then the current valuation may simply be the right one for a no-growth cash cow. Likewise, if free cash flow drops materially below $2.0B while debt remains around $9B, I would stop calling this mispriced. On the other hand, if Zoetis can re-accelerate to even 4%-5% annual revenue growth while holding operating margin near 45%-47%, I think the stock should rerate back toward at least 15x earnings, which would support a price in the low-to-mid $90s.
Grok Reading
Zoetis at $77 is a high-quality animal-health franchise being marked down as if mid-single-digit growth and 28% net margins are about to collapse. Annual revenue climbed from $7.78B in 2021 to $9.47B in 2025, a 5.3% CAGR, but the latest full year only grew 2.3% and recent quarters are essentially flat—$2.47B in the June 2026 quarter matches the year-ago print exactly, while the March quarter was up a thin 2.7%. What the market is underpaying for is the earnings power underneath that deceleration: gross margin holds at 71.8%, operating margin at 46.7%, and net margin at 28.2%, producing $2.67B of net income and $2.28B of free cash flow on only $621M of capex. At a 12.8x P/E, 7.9x EV/EBITDA and a ~7.1% FCF yield, the stock prices Zoetis like a no-growth generic manufacturer rather than the category leader with 35% ROIC. The quantitative fair-value composite near $94–$97 is directionally right; the multiple compression looks like a growth scare, not a franchise break.
The balance-sheet arithmetic is less flattering and is the real constraint on the bull case. Debt sits at $9.04B against $2.31B of cash and only $3.33B of equity, pushing debt-to-equity to 2.71. ROE of 80% is therefore heavily levered optics; the cleaner ROIC of 35% is the number that matters, and it remains excellent, but the capital structure leaves less room for error if livestock cycles or companion-animal spend soften further. Cash generation easily covers the load—operating cash flow of $2.90B dwarfs interest burden in a normal rate environment—and the 2.7% dividend is well covered, yet any aggressive buyback or bolt-on M&A funded with more debt would tighten the screw. Quarterly net income has also been choppy ($726M → $721M → $624M → $601M → $691M), so the “margin fortress” story is real on an annual basis but not immune to mix and timing noise.
I discount two claims in the prior model stack. First, “significant insider buying” and “coordinated insider buying signals undisclosed catalyst” do not match the tape: the last ten filings are almost entirely equity awards plus one gift. That is compensation mechanics, not open-market accumulation, and treating it as a bullish tell is a clear misread of the raw data. Second, the thesis evaluation’s 0-score stalemate underweights how cheap the starting multiple already is; when a 28% net-margin business with durable veterinary switching costs trades at roughly half a normal specialty-pharma earnings multiple, the bar for further downside is higher than the equal bull/bear mass implies. Revenue confidence flagged as “decelerating” is fair, but FCF CAGR of 18.7% over the period shows management has converted a slowing top line into accelerating cash, which is exactly what a mature earner is supposed to do.
The strongest case against my read is straightforward: growth has structurally reset lower. If companion-animal volumes settle at a 2–3% ceiling and livestock faces ongoing generic pressure, then 12.8x earnings is not a bargain—it is fair value for a 1.5–2% FCF grower, and the $94 DCF embeds growth the company may no longer deliver. The jump in leverage from prior periods (models flag D/E moving toward 2.71) can be read as financial engineering that juiced per-share metrics while the organic engine cooled. A smart opponent would also note that EV/revenue of 4.1x still embeds a premium to true generics, so any sustained sub-3% revenue print plus margin compression of even 200 bp would justify the current price or lower. I weigh this differently because the margin structure has not cracked—gross margin expanded from the low-70s toward 72% even as growth slowed—and FCF conversion remains pristine. The market is pricing a margin mean-reversion that five years of annual data have not shown.
What flips me is simple and near-term: two consecutive quarters of revenue growth back above 5% with operating margin holding ≥45% would confirm the deceleration was cyclical and push me to high-conviction undervalued; conversely, a full-year 2026 revenue print below $9.5B or net margin compressing under 25%, especially if accompanied by another step-up in net debt, would mark the stock as fairly valued to expensive at $77 and force a stance reversal.
Qwen Reading local experiment · off-panel
The numbers tell a story of a company that has peaked in its growth narrative and is now coasting. Revenue grew 5.3% CAGR over five years, sure, but the most recent comparable quarter — June 2026 at $2.47B versus June 2025 at $2.47B — is literally flat. Zero growth. Q1 2026's $2.26B versus Q1 2025's $2.20B is 2.7%, and the annual 2025 revenue of $9.47B versus 2024's $9.26B is 2.3%. Meanwhile, the net margin has drifted from 30% in September 2025 to 26.1% in December 2025 and 26.6% in March 2026, before recovering to 28% in June. The "margins expanding" thesis in the pre-flight intelligence is contradicted by the last three quarters of data. The 18.7% FCF CAGR that the momentum module highlights is a spinoff artifact — you're comparing post-Pfizer-separation years to pre-separation years, and the $2.28B FCF on $9.47B revenue (24% FCF margin) is the real number, which is excellent but not growing at 18%. Against this backdrop, the valuation synthesis landing at $94–98 fair value requires growth assumptions the data does not support. At 12.8x trailing earnings with 2.3% revenue growth and a margin that is, at best, stable, the multiple is reasonable but not the 22% upside opportunity the composite implies.
I want to flag a specific error in the prior analysis that materially distorts the bull case. The insider transaction log shows ten entries: one "G-Gift" of 6,650 shares and nine "A-Award" entries totaling roughly 2,875 shares. These are stock-based compensation grants and gifts to family members or trusts. They are not open-market purchases. The thesis evaluation's top bull argument — "coordinated insider buying signals undisclosed catalyst" at a 58/100 weight — is reading conviction into routine HR paperwork. No executive is writing a check at $77.295. This is the single most important correction in the entire briefing, because it removes what the models treat as a meaningful signal of insider confidence and replaces it with the mundane reality that Zoetis is granting RSUs on schedule.
The balance sheet is where the real tension lives. Total debt of $9.04B against equity of $3.33B gives a D/E of 2.71, and the thesis evaluation correctly notes this jumped from roughly 1.32. Net debt is $6.73B. Operating cash flow of $2.90B covers that, and the current ratio of 3.03 means liquidity is not in question, but the leverage ratio is doing a lot of work to inflate the 80% ROE. Strip out the leverage and you get a 35% ROIC, which is genuinely elite, but the capital structure is no longer the conservative, low-debt profile you'd expect from a "defensive compounder." If the 26–28% net margin slips another 100–200 basis points — and the Q4 2025 and Q1 2026 print suggests it already has — the interest burden on $9B of debt becomes a real drag on the $2.28B FCF line. The market may be right to apply a discount for this.
The strongest case against my skepticism is the quality of the underlying business. A 72% gross margin, 47% operating margin, 35% ROIC, and 24% FCF margin in a sector where the end customer is a pet owner who will not skip a round of vaccines or a dewormer because of a 3% GDP dip is a genuinely durable franchise. At 7.9x EV/EBITDA and a 2.7% dividend yield, you are not paying a growth premium; you are paying a quality premium at a reasonable price. The companion-animal spending base is structurally different from livestock, where the bear case about commoditization has more teeth, and the $9.47B revenue base is diversified enough that no single franchise's genericization is existential. If I am wrong, it is because I am underweighting the defensive character of the cash flows and over-penalizing a 2.3% growth print that may be a cyclical trough rather than a structural ceiling.
What would flip me: a Q3 2026 (September) print showing revenue growth reaccelerating above 4% year-over-year with net margin back above 29% would validate that the 26% prints were a one-time charge or mix shift, and I would upgrade to undervalued. Conversely, if the next two quarters show revenue flat or declining and the company announces a further debt raise or a dividend cut to manage the $9B load, the 12.8x multiple becomes expensive for a company that is no longer growing, and I would move to overvalued. A concrete catalyst — a new pipeline approval in companion animal therapeutics, a strategic acquisition funded by the existing debt capacity, or a buyback program that actually reduces the equity base — would also change the equation, because right now the stock is a quality business at a fair price with no visible catalyst to re-rate it.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Zoetis presents as a textbook mature compounder in animal health. Revenue has grown every year from 7.78B (2021) to 9.47B (2025), gross margin has expanded from 70.4% to 71.8%, and operating margin has climbed from 44.7% to 46.7% — durable pricing power and operating leverage rather than a one-off. Net income (2.04B to 2.67B) and FCF (2.28B in 2025) both scale, and OCF/NI at 1.05x with accruals at -1% of assets and a Beneish M of -2.44 indicate reported earnings are backed by cash, not accrual games. Per-share discipline is real: diluted share count fell from 476.7M to 443.8M (-1.8% CAGR), SBC is a modest 0.9% of revenue, and buybacks exceed SBC by 25x - shareholders are getting concentrated, not diluted. The balance sheet is the one soft spot: net debt of roughly 6.7B against 2.3B cash means liquidity is a constraint, but with Altman Z of 4.73 and 2.28B annual FCF, coverage is comfortable. Insider tape is mostly awards, option exercises, and gifts - the 'significant insider buying' framing overstates it; there are no directional P-code open-market purchases visible in the recent tape. Still, no distress signals, no selling wave, and no accounting oddities.
Verify before trusting this (5)
- Debt maturity schedule and interest coverage detail behind the 6.7B net debt
- Whether 2025 revenue deceleration reflects the Librela/OA pain franchise or broader companion-animal softness
- Segment mix and customer/species concentration (companion vs livestock) in the 10-K
- Any pending litigation or regulatory issues around key products (e.g., Librela safety signals)
- Confirmation that the flagged insider 'buying' is not simply mislabeled awards/exercises
Price is $77.30 against a composite fair value of $97.86 and a signal-adjusted FV of $94.37, implying roughly 22% upside. But the three methods sprawl: DCF at $74.35 and EPV floor at $72.46 both sit slightly BELOW the current price, while the anchored P/E of $170.26 is the outlier pulling the composite up. Treating the anchored-PE as a runaway multiple (it implies a re-rating to premium historical multiples that a mature, decelerating business no longer deserves) and leaning on DCF/EPV, deserved value is closer to $75-85 - meaning the stock is fair to modestly cheap, not deeply discounted. Earnings quality is high (no haircut) and the business is Strong-grade, which supports paying toward the upper end of that band. What is priced in: continued mid-single-digit growth, stable margins, and ongoing buybacks - reasonable, not heroic. The bear case (post-pandemic normalization, livestock commoditization, 2025 deceleration) is real but not catastrophic. Margin of safety exists but is thin; this is a 'buy a good business at a reasonable price' setup, not a dislocation.
Verify before trusting this (4)
- 2025 organic growth trajectory by segment (companion vs livestock) in next 10-Q
- Librela/Solensia uptake and any adverse-event overhang
- Guidance revisions and FX impact
- Capital allocation - buyback pace vs leverage given already-levered balance sheet
Zoetis sits in a mildly constructive macro tape (regime +18, VIX 15.9) but with a 0.73 beta and defensive healthcare profile, the market weather barely moves the needle here. The dominant sentiment forces are name-specific and cross-cutting: an August guidance cut and 7% US revenue decline broke the 'recession-resistant pet spending' pillar of the bull narrative, yet the stock has been climbing on offsetting positives - Michael Burry disclosing a long, back-to-back FDA Emergency Use Authorizations for Simparica Trio, and a Q2 EPS beat. The result is a stock that rallied through bad guidance, which tells you sentiment is already washed-out and marginal buyers are stepping in on any positive catalyst. The narrative archetype is steady-compounder with moderate intensity and low cult - so no mania to unwind, no story collapse in progress, just a mature-growth debate. Analyst tone implied by the news flow is skeptical ('Can It Support a Slowing U.S. Business?', 'Divided Business') but not capitulating. Net pressure is roughly balanced: the negative fundamental narrative is offset by a value-buyer bid (Burry) and a string of regulatory wins that give bulls something to point to.
Verify before trusting this (4)
- Whether US companion animal comps stabilize in Q3 or continue to deteriorate - that is the single biggest narrative pivot
- Sell-side target revisions in the next 4-6 weeks post-guide-down - direction of drift
- Any follow-through buying tied to the Burry disclosure vs it fading as a one-day event
- Simparica Trio prescription/uptake data on the screwworm indication to validate pipeline optionality
The world is getting more, older, and more medicalized pets while getting more cost-conscious about the vet bill — a volume/pricing tug-of-war that favors incumbents with the prescriber relationship but no longer gifts them double-digit growth. Simultaneously, animal health has stopped being a competitive vacuum: rivals now target the exact high-margin chronic indications that built Zoetis's premium. Rates at 4.74% and a slowing sector mean the market will pay for demonstrated durability, not narrative. Zoetis's franchise structure survives all of this; its growth RATE does not survive it unchanged.
When we made this prediction on Aug 26, 2026, ZTS was $78.03. We expect it to be $85.10 by Feb 2027, and we consider it great value under $68.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 26, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
adjusted_earnings
flips up 25%
cost_of_capital
flips down 25%
shares
flips down 25%